Results 51 to 60 of about 519,396 (228)

Proton-pump inhibitor use is associated with a broad spectrum of neurological adverse events including impaired hearing, vision, and memory. [PDF]

, 2019
Proton-pump inhibitors, PPIs, are considered effective therapy for stomach acid suppression due to their irreversible inhibition of the hydrogen/potassium pump in the gastric parietal cells. They are widely prescribed and are considered safe for over-the-
Abagyan, Ruben, Alpatty, Sama, Atayee, Rabia S, Lee, Kelly C, Makunts, Tigran   +4 more
core   +1 more source

Safety profile of oxcarbazepine: results from a prescription-event monitoring study [PDF]

, 2010
Purpose: To monitor safety of oxcarbazepine, prescribed in primary care in England, using prescription-event monitoring (PEM). Methods: Postmarketing surveillance using observational cohort technique of PEM.
Buggy, Y., Fogg, Carole, Layton, D., Shakir, S.   +3 more
core   +1 more source

Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors: Investigating the Likelihood of Interaction through the Vaccine Adverse Event Reporting System and VigiBase [PDF]

, 2021
Milo Gatti, Emanuel Raschi, Ugo Moretti, Andrea Ardizzoni, Elisabetta Poluzzi, Igor Diemberger   +5 more
openalex   +1 more source

Prevalence and consequences of patient safety incidents in general practice in the Netherlands: a retrospective medical record review study [PDF]

, 2016
BACKGROUND Patient safety can be at stake in both hospital and general practice settings. While severe patient safety incidents have been described, quantitative studies in large samples of patients in general practice are rare.
Gaal, Sander, Lankveld, Henrike, van Weel, Chris, Verstappen, Wim, Wensing, Michel, Wolters, Rene   +5 more
core   +1 more source

Adverse event profile of lorazepam: a real-world pharmacovigilance study using the FDA adverse event reporting system database

Frontiers in Pharmacology
IntroductionAnxiety diagnoses have surged recently during and after the COVID-19 pandemic. Lorazepam is widely recognized for its efficacy in treatment of anxiety, as well as insomnia, etc.
Zhengkang Su, Zhengwei Huang, Xiaoyu Chen, Xiaoyu Chen, Xi Li   +4 more
doaj   +1 more source

Patient safety in dentistry: development of a candidate 'never event' list for primary care [PDF]

, 2017
Introduction The 'never event' concept is often used in secondary care and refers to an agreed list of patient safety incidents that 'should not happen if the necessary preventative measures are in place'.
A Milstein, A Saksena, B Perea-Perez, C de Wet, C Vincent, E Bailey, E Bailey, E Bailey, HH Chang, HM Pinsky, HP Beddis, HR Zahiri, I. Black, J Pill, Johnny Saldana, JS Lee, MN Pemberton, MN Pemberton, MR Lynn, O Peleg, P. Bowie, S Hignett, S Thusu   +22 more
core   +2 more sources

Exploration of adverse event profiles for cefotaxime: a disproportionality analysis using the FDA adverse event reporting system

BMC Pharmacology and Toxicology
Background Cefotaxime has been widely used in the clinical treatment of infections. However, there is still a lack of systematic researches for the adverse event profiles of cefotaxime through large-scale post-marketing monitoring.
Cheng Jiang, Jiancheng Qian, Yingyan Lu, Junxian Zheng   +3 more
doaj   +1 more source

Safety assessment of laronidase: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS)

Frontiers in Pharmacology
ObjectiveLaronidase is the first drug of enzyme replacement therapy approved for the treatment of mucopolysaccharidosis type I (MPS I). However, its adverse events (AEs) have not been investigated in real - world settings.
Zhuomiao Lin, Junling Xue, Meiqing Yang, Xihui Yu, Jiahong Zhong   +4 more
doaj   +1 more source

Safety assessment of gemtuzumab ozogamicin: real-world adverse event analysis based on the FDA Adverse Event Reporting System

Frontiers in Medicine
ObjectiveTo mine adverse drug events (ADEs) following the use of gemtuzumab ozogamicin based on the FDA Adverse Event Reporting System (FAERS), and to provide references for the safety assessment of clinical drug use.MethodsWe obtained reports of adverse
Xuexue Liu, Fang Wu, Zhuoyan Li, Chenxi Li, Xinyu Li, Yining Yuan, Xinyu Sun, Ying Du, Xiao Du, Siliang Wang, Peipei Xu   +10 more
doaj   +1 more source

DARE-SAFE: Denominator-Adjusted Rate Estimates of Substance Adverse Events Frequency Evaluation in Pharmaceuticals and Vaccines

Pharmacoepidemiology
Background/Objectives: Controversy exists over the use of passive reporting systems, especially the Vaccine Adverse Event Reporting System, in risk assessment.
Matthew Halma, Joseph Varon
doaj   +1 more source